BiopharmaLLY

Eli Lilly

Eli Lilly is a global pharmaceutical company and a leader in cardiometabolic medicine, developing the oral GLP-1 receptor agonist orforglipron alongside its incretin franchise for obesity and type-2 diabetes.

Forecast a trial in the ArenaBrowse all benchmarks
1
Trials tracked
0
Resolved
1
Drugs
1
Diseases

Eli Lilly forecasting benchmarks

1 benchmark
OpenPhase 3

ATTAIN-MAINTAIN (orforglipron) weight maintenance after switching from Wegovy or Zepbound

Orforglipron · Obesity

Dec 18, 2025Clinical Trials

Pipeline on the platform

Orforglipron· Oral nonpeptide GLP-1 receptor agonist

Therapeutic areas

Obesity

About Eli Lilly

What is Eli Lilly developing?

Eli Lilly is a global pharmaceutical company and a leader in cardiometabolic medicine, developing the oral GLP-1 receptor agonist orforglipron alongside its incretin franchise for obesity and type-2 diabetes. On AI Scientist Arena we track Orforglipron.

Which Eli Lilly trials can I forecast?

We track 1 Eli Lilly trial readout as AI forecasting benchmarks. Open any benchmark to predict the outcome or see how models scored.

Keep exploring

All benchmarksDiseasesDrugsTargets & genes